5 ms·
Meta analysis of 60 Ivermectin studies: https://ivmmeta.com/ https://ivmmeta.com/
by 0-_-0 5y ago
Meta analysis of 60 Ivermectin studies:
https://ivmmeta.com/ https://ivmmeta.com/
- xtracto 5y agoIt blows my mind the way the "mainstream" has closed their eyes to Ivermectin. Here in Mexico it was use in children to cure Lice, and also sometimes used as a "once a year" dewormer. This means that the safety profile is incredibly low. However, even after repeated cases of it helping with COVID19, people just refuse to even talk about it. Luckily, here in Mexico you don't need a prescription to get it, so that anyone can use it if they want to.
- m-p-3 5y agoDifferent websites (such as https://ivmmeta.com/ https://ivmmeta.com/, https://c19ivermectin.com/ https://c19ivermectin.com/, https://tratamientotemprano.org/estudios-ivermectina/ https://tratamientotemprano.org/estudios-ivermectina/, among others) have conducted meta-analyses with ivermectin studies, showing unpublished colourful forest plots which rapidly gained public acknowledgement and were disseminated via social media, without following any methodological or report guidelines. These websites do not include protocol registration with methods, search strategies, inclusion criteria, quality assessment of the included studies nor the certainty of the evidence of the pooled estimates. Prospective registration of systematic reviews with or without meta-analysis protocols is a key feature for providing transparency in the review process and ensuring protection against reporting biases, by revealing differences between the methods or outcomes reported in the published review and those planned in the registered protocol. These websites show pooled estimates suggesting significant benefits with ivermectin, which has resulted in confusion for clinicians, patients and even decision-makers. This is usually a problem when performing meta-analyses which are not based in rigorous systematic reviews, often leading to spread spurious or fallacious findings. Concluding, research related to ivermectin in COVID-19 has serious methodological limitations resulting in very low certainty of the evidence, and continues to grow. The use of ivermectin, among others repurposed drugs for prophylaxis or treatment for COVID-19, should be done based on trustable evidence, without conflicts of interest, with proven safety and efficacy in patient-consented, ethically approved, randomised clinical trials. Source: Misleading clinical evidence and systematic reviews on ivermectin for COVID-19; https://ebm.bmj.com/content/early/2021/05/26/bmjebm-2021-111678 https://ebm.bmj.com/content/early/2021/05/26/bmjebm-2021-111...
- 0-_-0 5y agoThe only specific ctiticism is the following sentence, the rest is designed to create fear, uncertainty and doubt: These websites do not include protocol registration with methods, search strategies, inclusion criteria, quality assessment of the included studies nor the certainty of the evidence of the pooled estimates. This is false. The ivmmeta.com page says: Typical meta analyses involve subjective selection criteria, effect extraction rules, and study bias evaluation, which can be used to bias results towards a specific outcome. In order to avoid bias we include all studies and use a pre-specified method to extract results from all studies (we also present results after exclusions). They also compare prospective and retrospective studies and see no significant difference. You could have at least scrolled through the page before blindly copy-pasting something from Google.
- gus_massa 5y agoOne of the problem with meta analysis is the lack of pre-registration of most of the studies about ivermectin. There are many studies in many places. Imagine just for a moment that some new drug has no effect. Anyway, 1/20 of them will get a fake statistical significant result. The problem is that this study with a fake good result has a high chance of been published. The other 19 have a high chance of not been published, because the doctors lost interest, because the journal don't like null results, or other similar reasons. So if you make a review of the published studies, you will only find only/mostly the ones that get a good result due to a fluke. This is not an imaginary problem, this is a known problem. Imagine Big Pharma has a new drug, and they want to it approved. They can hire 100 universities/hospitals to run a clinical study, suggest that only the ones with a good fluke result get published and then they get about 5 good papers about the drug. Perhaps they don't even have to make a suggestion, because it's boring to write a paper about a drug that does not work so the medic just don't write it, and it's boring to read a paper about a drug that does not work so the journal just publish it. It's the same effect, and nobody is lying ;) . The solution for this is pre-registration. Before starting the trial, you must register it, explain what drugs you are going to use, what are you going to measure. With pre-registration, now the 100 studies are public. If you later find 5 good and 95 inconclusive or bad or disappeared, you know in the meta analysis the 5 good studies are only flukes.